Seventeen patients who developed hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation were treated with recombinant tissue plasminogen activator (rtPA) with or without heparin. rtPA was started a median of 13 days post transplant (range 4-35). All patients received rtPA at a dose of 10 mg/day as a starting dose, and 12 patients also received heparin (1500 U bolus; then 100 U/kg/day as a continuous i.v. infusion). The median number of days of rtPA therapy was 2.5 (1-12). The median total serum bilirubin level was 116 mmol/l (range 63-194) at the beginning of treatment. Six patients showed a response to rtPA treatment (29%). It was observed that by day 2 of rtPA therapy, bilirubin levels in responders showed a downwards trend as compared to those in nonresponders. In all except one patient this response was observed after two doses of rtPA. Seven out of the 11 non-responders had a past history of liver dysfunction, compared with none of the responders. There were no differences between the two groups in terms of day of onset of liver dysfunction, manifestations of disease, maximum bilirubin and creatinine levels, and day of commencing treatment. No patient experienced severe hemorrhagic complications during therapy. Four responders survived for more than 100 days compared to none of the non-responders. Probability of survival was 33% at day 100. It is difficult to unequivocally establish the role of rtPA in the treatment of VOD. The importance of bilirubin levels on days 2 or 3 of therapy in predicting outcome should be established, as should the optimum dose of rtPA and optimum duration of therapy.
clinical syndrome characterized by hyperbilirubinemia, hepatomegaly and fluid retention, 2, 3 and results from damage to structures in zone 3 of the liver acinus. 4 In patients who have undergone hematopoietic stem cell transplantation, chemoradiotherapy-induced endothelial cell damage is likely to be responsible for the pathogenesis of vessel obstruction. 5 Treatment of established VOD has primarily been supportive and any specific measures have resulted in little impact on outcome. Based on the available evidence for involvement of hemostatic mechanisms and cytokines in the pathogenesis of VOD, [6] [7] [8] anti-thrombotic and anti-cytokine agents have been assessed for their role in treatment. Recombinant tissue plasminogen activator (rtPA) is a thrombolytic agent which has a high specificity for fibrinbound plasminogen, and significant clot specificity. 9 It has been used for the treatment of severe hepatic VOD with variable success. [10] [11] [12] Here, we report our experience of rtPA used to treat hepatic VOD.
Materials and methods

Patients
The prospectively maintained database at the Royal Marsden Hospital identified 17 patients with hepatic VOD treated with rtPA, between May 1995 and May 1998. Nine fulfilled the Seattle criteria for VOD 1, 2 and eight more also fulfilled the Baltimore criteria.
3 Tables 1 and 2 summarize patient characteristics. Sixteen patients had received previous chemotherapy, four previous radiotherapy, and two interferon. Eight patients had a previous history of hepatic dysfunction, and five had abnormal liver function at transplant. All 17 patients had normal renal function pre-transplant. Patients with active bleeding or neurological problems were not treated with rtPA in spite of having a clinical diagnosis of VOD. All patients underwent baseline coagulation studies together with blood counts, liver and renal function tests. All parameters were monitored daily. An attempt was made to undertake liver ultrasound examinations as soon as hepatic VOD was suspected. Invasive diagnostic procedures were not performed.
Conditioning regimen and GVHD prophylaxis
Conditioning regimens used are shown in Table 1 . Total body irradiation (TBI) was used in 11 patients, total lymphrtPA for the treatment of hepatic VOD S Kulkarni et al 804 oid irradiation (TLI) and chemotherapy in one patient, and five received chemotherapy only conditioning. Fourteen allograft patients received a combination of short-course methotrexate (MTX) and cyclosporin A (CsA). Two patients received CsA alone. Eight patients developed acute graft-versus-host disease (GVHD) and were treated with additional methylprednisolone.
Thrombolytic treatment
Thrombolytic treatment is described in Table 3 . Patients either received rtPA alone or with heparin. rtPA was started at a median of 13 days post hematopoetic rescue (range: 4-35). The mean total dose was 25 mg (range 10-120 mg), and the median total days of administration was 2.5 days (range 1-12 days). At the start of thrombolytic therapy, the median total serum bilirubin was 116 mmol/l (range , and the median serum creatinine was 155 mmol/l (range 59-551). Median weight gain at the time of starting rtPA was 4.4% (range: 1.6-13%) over the baseline.
The INR was maintained between 1.0 and 1.4 while patients were receiving heparin. Heparin was discontinued if the INR rose above this level, or if the APTT was more than 1.5 times the upper level of the institutional normal. The median platelet count at the start of therapy was 15 ϫ 10 9 /l (range 3-51).
Results
Of the 17 patients with a clinical diagnosis of hepatic VOD who received rtPA, 12 also received heparin with the rtPA for 10 days. All patients had jaundice, 12 had unexplained weight gain, 12 had hepatomegaly and eight had ascites. The median total serum bilirubin level at diagnosis of VOD was 48 mmol/l (range 34-80). Six patients had abnormal serum creatinine levels (defined as doubling of the preconditioning serum creatinine) at diagnosis of VOD (median 86 mmol/l; range 48-198). The median weight gain at diagnosis of VOD was 3.5% (range 0.3%-10.4%) from baseline.
Efficacy of treatment
Four of 17 patients experienced prompt decreases in their serum bilirubin levels, and in one the bilirubin stabilized. The mean decrease in total serum bilirubin was 36.7% (range: 16-53%), and 56.6% (range 33-67%) at 48 and 96 h after commencement of rtPA ( Figure 1 ). After 10 days of rtPA treatment, the mean decrease in serum bilirubin for these five patients was 72% (range 65-80%).These five patients had also received heparin from the time of starting rtPA. One additional patient had a prompt reduction in his weight gain and his bilirubin levels decreased over 8 days and eventually normalized. Eleven of 17 patients had no response to thrombolytic therapy and experienced a progressive increase in bilirubinemia. Twelve patients died early post-transplant due to hepatic and multiorgan failure. The mean total serum bilirubin was 159 mmol/l (range 150-194 mmol/l) at the start of therapy in the five patients who responded. The mean total serum bilirubin level was 102 mmol/l (range 63-165 mmol/l) at the start of therapy in the non-responders. After initiation of therapy with rtPA, the responders experienced a reduction in weight (median 3.2%; range minus 6.4-1.7%), as against non-responders who gained weight (median 7.8%; range minus 4-17.5%) from baseline on the 14th day after therapy (Figure 2) .
The median dose of rtPA was 25 mg (range 20-40 mg) administered over 2 days (range 2-4 days) in the five responders. The median dose of rtPA was 35 mg (range 10-120 mg) administered over 2 days (range 1-12 days) in the 11 non-responders. rtPA was started at a median of 7 days (range 3-9 days) in responders and at a median of 3 days (range 1-12 days) in non-responders. The median serum creatinine at the start of rtPA therapy was 161.5 mmol/l (range 114-198 mmol/l) in responders, and 185.1 mmol/l (range 59-551 mmol/l) in non-responders.
Bleeding
None of the 17 patients experienced major hemorrhagic complications during rtPA treatment. Two had mild and controllable bleeding (melena and oral mucositis), which was not totally attributable to the rtPA therapy.
Survival
Only two of the five responders are alive with normal liver function at 895 and 1090 days post-transplant. In the other three responders VOD resolved, but they died after 116, 120 and 158 days post-transplant. One died from infection and two from leukemia relapse. The 11 non-responders died early (median 26 days, range 13-83 days). The cause of death was multiorgan failure in seven patients, leukemia relapse in two, radiation pneumonitis in one and severe liver dysfunction in one. 
Discussion
The pathogenesis of VOD is complex. Several laboratory and clinical criteria indicate that, at some stage, blood clotting and inflammation result in hepatic damage. 6, 13, 14 Deficiency of protein C, factor VII and antithrombin III has been observed in some patients with VOD 7,15 but it is not clear whether these agents are involved in the pathogenesis of VOD or are merely epiphenomena. Also, such markers are not unequivocally useful in identifying patients at risk of developing hepatic dysfunction and it is unclear whether therapeutic interventions designed to alter levels of these markers prevent development of hepatic disease.
The mortality associated with severe VOD is high, 1 therapeutic options are limited and newer techniques such as orthotopic liver transplantation may not be practical for all patients. 10 The agents which have been proposed for treating VOD include prostaglandin E1, rtPA and anticytokine drugs, but efficacy and usefulness of these therapies have not been evaluated in a prospective randomized fashion, although rtPA seems to be the most promising agent to date. 11 Defibrotide, an agent which acts on the vascular endothelial cells has also been tried recently. 16 Baglin et al 17 first used rtPA for treating VOD, with a successful outcome. The rationale behind the use of thrombolytic agents in VOD is the pathologic implications of the altered hemostasis. The preliminary results of one retrospective study evaluating the role of rtPA in VOD were encouraging, 11 but in the final analysis, effectiveness of the agent could not be unequivocally established. 12 It was particularly not recommended for patients who had already developed multiorgan dysfunction. 17 In our series, five patients showed a response to rtPA treatment and the bilirubin level stabilized in one, giving a response rate of 35.3%. However, only two of these patients are still alive. Three patients died of infections or relapse of leukemia without evidence of liver dysfunction, and one further patient died of multiorgan failure. This poor response rate could be due to the delayed onset of rtPA treatment (median 13 days post transplant), but it was of interest that the responders had higher mean bilirubin levels at the start of rtPA therapy and also started the treatment later than did the non-responders (7 vs 3 days). Even though it has been suggested that early initiation of therapy may be more beneficial, 12 in our experience this does not seem to be unequivocally true, and other successful outcomes have been reported despite delayed initiation of therapy. 16, 18 Most previous reports have defined response to treatment as a reduction in total serum bilirubin by 50% within 10 days of the start of treatment with most responses being observed within 48-96 h. 12 One of our responders improved both clinically and in terms of his liver function tests relatively late at 8 days (reduction in total serum bilirubin by 31% on day 10), but even though the temporal connection between rtPA administration and start of recovery does not suggest that these two events are related, spontaneous recovery in this patient would seem to be unlikely. Figure 1 shows the daily mean bilirubin levels of responders and non-responders. It can be seen that by day 2 the bilirubin levels are decreasing in responders as compared to non-responders. Whether the trend in bilirubin on day 2 of treatment can be used to decide upon the most appropriate duration of rtPA therapy requires evaluation in larger studies.
There was a consistent reduction in weight by day 2 in responders as compared to non-responders (Figure 2) . Hence, response to rtPA treatment was uniform for both weight gain and elevated bilirubin levels.
Patient numbers in this study are insufficient to allow evaluation of the role of established prognostic factors on response to rtPA. However, it was apparent that none of the patients who responded to rtPA had a previous history of liver dysfunction during earlier therapy. The hepatic manifestations of VOD did not differ sufficiently between responders and non-responders to enable any conclusions to be drawn concerning prediction of response.
Although we saw no serious bleeding complications with the combined use of rtPA and heparin, two patients had minor bleeding problems. This stresses the fact that lifethreatening bleeding is a possibility and these drugs should only be used in selected patients with very careful monitoring. One possible reason for the lack of serious bleeding problems may be the dose of rtPA used. The median dosage used in this series (25 mg) was much lower than the doses used by others. 12, 19 All responders except one experienced benefit after two doses of rtPA, and this patient required four doses, raising the issues of optimal dose and duration of therapy in nonresponders and whether prolonged administration of higher doses would result in better response rates.
Median survival in our patient group was 158 days (116-700 days) in responders and 29 days (13-72 days ) in nonresponders. All five responders survived for more than 100 days compared with none of the non-responders, but this may in part be a reflection of the fact that the nonresponders tended to either already have, or to develop an increased number of additional problems than did the responders.
One aspect of VOD which renders evaluation of response to any treatment difficult is the fact that in 25% to 40% of patients, the disease may run a self-limiting course. Whether the responders in this study had a self-limiting, mild to moderate form of VOD which would have resolved spontaneously, or whether their disease would have become severe and life-threatening without rtPA is impossible to ascertain. It is also unclear from the data in the literature and from our results whether the predictive model proposed by Bearman et al 20 will be useful in helping to decide which patients will benefit from any newer anti-VOD therapies which may become available.
In conclusion, it can be said that the role of rtPA in the treatment of VOD is not unequivocally established. It is difficult to identify the group of patients who may benefit from thrombolytic therapy. The drug needs to be used with careful monitoring. Optimum duration of therapy with rtPA A is undefined but continuation of treatment beyond 72 to 96 h may not confer additional benefit. Better strategies for prevention and treatment of VOD are urgently needed, and the newer agents such as defibrotide, anti-IL-1 and TNF␣ antibodies may prove to be more efficacious.
